145 related articles for article (PubMed ID: 26075272)
1. Ecdysteroids sensitize MDR and non-MDR cancer cell lines to doxorubicin, paclitaxel, and vincristine but tend to protect them from cisplatin.
Martins A; Sipos P; Dér K; Csábi J; Miklos W; Berger W; Zalatnai A; Amaral L; Molnár J; Szabó-Révész P; Hunyadi A
Biomed Res Int; 2015; 2015():895360. PubMed ID: 26075272
[TBL] [Abstract][Full Text] [Related]
2. Significant activity of ecdysteroids on the resistance to doxorubicin in mammalian cancer cells expressing the human ABCB1 transporter.
Martins A; Tóth N; Ványolós A; Béni Z; Zupkó I; Molnár J; Báthori M; Hunyadi A
J Med Chem; 2012 Jun; 55(11):5034-43. PubMed ID: 22578055
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
4. Nitrogen-containing ecdysteroid derivatives vs. multi-drug resistance in cancer: Preparation and antitumor activity of oximes, oxime ethers and a lactam.
Vágvölgyi M; Martins A; Kulmány Á; Zupkó I; Gáti T; Simon A; Tóth G; Hunyadi A
Eur J Med Chem; 2018 Jan; 144():730-739. PubMed ID: 29291440
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
[TBL] [Abstract][Full Text] [Related]
6. Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells.
Zhang DM; Li YJ; Shu C; Ruan ZX; Chen WM; Yiu A; Peng YH; Wang J; Lan P; Yao Z; Fung KP; Fu LW; Chen ZS; Ye WC
Anticancer Drugs; 2013 Jun; 24(5):441-54. PubMed ID: 23466650
[TBL] [Abstract][Full Text] [Related]
7. Backstabbing P-gp: Side-Chain Cleaved Ecdysteroid 2,3-Dioxolanes Hyper-Sensitize MDR Cancer Cells to Doxorubicin without Efflux Inhibition.
Hunyadi A; Csábi J; Martins A; Molnár J; Balázs A; Tóth G
Molecules; 2017 Jan; 22(2):. PubMed ID: 28125071
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
9. Reversal of ABCB1-related multidrug resistance by ERK5-IN-1.
Wang F; Li D; Zheng Z; Kin Wah To K; Chen Z; Zhong M; Su X; Chen L; Fu L
J Exp Clin Cancer Res; 2020 Mar; 39(1):50. PubMed ID: 32164732
[TBL] [Abstract][Full Text] [Related]
10. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
11. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship study of novel 2-aminobenzofuran derivatives as P-glycoprotein inhibitors.
Chen CY; Lin CM; Lin HC; Huang CF; Lee CY; Si Tou TC; Hung CC; Chang CS
Eur J Med Chem; 2017 Jan; 125():1023-1035. PubMed ID: 27810590
[TBL] [Abstract][Full Text] [Related]
13. Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance.
Huang BY; Zeng Y; Li YJ; Huang XJ; Hu N; Yao N; Chen MF; Yang ZG; Chen ZS; Zhang DM; Zeng CQ
Int J Oncol; 2017 Jul; 51(1):257-268. PubMed ID: 28534954
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of novel ecdysteroid dioxolanes as MDR modulators in cancer.
Martins A; Csábi J; Balázs A; Kitka D; Amaral L; Molnár J; Simon A; Tóth G; Hunyadi A
Molecules; 2013 Dec; 18(12):15255-75. PubMed ID: 24335576
[TBL] [Abstract][Full Text] [Related]
15. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.
Zhang DM; Shu C; Chen JJ; Sodani K; Wang J; Bhatnagar J; Lan P; Ruan ZX; Xiao ZJ; Ambudkar SV; Chen WM; Chen ZS; Ye WC
Mol Pharm; 2012 Nov; 9(11):3147-59. PubMed ID: 23046348
[TBL] [Abstract][Full Text] [Related]
16. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
Duan Z; Choy E; Jimeno JM; Cuevas Cdel M; Mankin HJ; Hornicek FJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1121-9. PubMed ID: 18828019
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
18. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
19. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
He D; Zhao XQ; Chen XG; Fang Y; Singh S; Talele TT; Qiu HJ; Liang YJ; Wang XK; Zhang GQ; Chen ZS; Fu LW
PLoS One; 2013; 8(1):e54181. PubMed ID: 23349819
[TBL] [Abstract][Full Text] [Related]
20. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
